Enteral feeding during cyclooxygenase inhibitor treatment for patent ductus arteriosus: A systematic review
Pediatrics International · 2026-01 · 68 (1)
DOI: 10.1111/ped.70338 ↗At a glance
Systematische Übersicht in Pediatrics International, published online on 2026-02-10. Written by Gakuto Ujiie and 7 co-authors. Institution: Department of Pediatrics, Showa Medical University, Shinagawa, Japan. Major MEDLINE topics: Ductus Arteriosus, Patent, Enteral Nutrition, Cyclooxygenase Inhibitors, Infant, Premature, Diseases. Cited 1 times so far (Crossref); 35 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Background
This study evaluated the effect of modifying enteral feeding during cyclooxygenase inhibitor (COXI) treatment on patent ductus arteriosus (PDA) in preterm infants.
Methods
We searched MEDLINE, EMBASE, CENTRAL, CINAHL, and ICHUUSHI databases for randomized and nonrandomized controlled trials, checked the references lists and major clinical trials. Non‐human and non‐English studies were excluded. Evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation. Preterm infants born before 37 weeks of gestation are treated with COXIs for PDA, including indomethacin and ibuprofen. The primary outcomes were the composite outcome of necrotizing enterocolitis (NEC) or gastrointestinal perforation and its components (NEC and gastrointestinal perforation).
Results
Two randomized controlled trials ( n = 303) and one retrospective cohort study ( n = 261) were included (total: n = 564). No significant differences were observed in the composite gastrointestinal outcome (risk ratio [RR]: 1.10, 95% confidence interval [CI]: 0.51–2.37; 1 study, 177 infants, very low certainty of evidence [CoE]), NEC (RR: 1.01, 95% CI: 0.47–2.15; 2 studies, 300 infants, very low CoE), or gastrointestinal perforation (RR: 1.94, 95% CI: 0.25–14.81; 2 studies, 300 infants, very low CoE) between discontinuation and continuation of enteral feeding. Discontinuation of enteral feeding resulted in a significantly lower rate of surgical closure for PDA compared to continuation (RR: 0.56, 95% CI: 0.37–0.86; 1 study, 177 infants, low CoE).
Conclusions
Neither discontinuation nor continuation of enteral feeding significantly affected the composite gastrointestinal outcome and its components (NEC and gastrointestinal perforation).
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pediatrics, Showa Medical University, Shinagawa, Japan.
- Department of Neonatology, Kanagawa Children's Medical Center, Yokohama, Japan.
- Department of Nursing, Toyama Prefectural University, Imizu, Japan.
- Department of Nursing Faculty of Human Health Sciences, Shunan University, Shunan, Japan.
- Department of Neonatology, Kameda Medical Center, Kamogawa, Japan.
- Division of Neonatology, Department of Pediatrics, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
ORCID profiles: Eriko Kobayashi, Kosuke Tanaka
Cite
APA
Ujiie, G., Kobayashi, E., Inoue, M., Sakurai, M., Sakurai, Y., Tanaka, K., Isayama, T., & Toyoshima, K. (2026). Enteral feeding during cyclooxygenase inhibitor treatment for patent ductus arteriosus: A systematic review. Pediatrics International, 68(1). https://doi.org/10.1111/ped.70338
Vancouver
Ujiie G, Kobayashi E, Inoue M, Sakurai M, Sakurai Y, Tanaka K, et al. Enteral feeding during cyclooxygenase inhibitor treatment for patent ductus arteriosus: A systematic review. Pediatrics International. 2026;68(1). doi:10.1111/ped.70338
BibTeX
@article{Ujiie2026,
author = {Ujiie, Gakuto and Kobayashi, Eriko and Inoue, Miyuki and Sakurai, Motoichiro and Sakurai, Yuko and Tanaka, Kosuke and Isayama, Tetsuya and Toyoshima, Katsuaki},
title = {Enteral feeding during cyclooxygenase inhibitor treatment for patent ductus arteriosus: A systematic review},
journal = {Pediatrics International},
year = {2026},
volume = {68},
number = {1},
doi = {10.1111/ped.70338}
}
EUVIMED